ArticleInternational neurourology journal2026
Differential Effects of Antidepressants on Hypothalamic Serotonin Levels in Rats: An In Vivo Microdialysis Study.
Article in International neurourology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeAntidepressants can induce urinary retention, difficulty in voiding, and delayed micturition, effects thought to result from detrusor relaxation and increased urethral sphincter tone mediated by enhanced central serotonergic activity. However, direct measurements of brain serotonin following antidepressant treatment remain limited. The relative risk of voiding difficulty across different antidepressant classes may help guide individualized antidepressant selection. This study aimed to assess changes in hypothalamic serotonin levels after administration of various antidepressants using an animal microdialysis model.
methodsMale Sprague-Dawley rats (280-330 g) were randomly assigned to 5 groups (n=8 per group) and received intraperitoneal injections of saline, clomipramine, fluoxetine, sertraline, or paroxetine (10 mg/kg). A microdialysis probe was stereotaxically implanted in the hypothalamus and perfused with artificial cerebrospinal fluid. Dialysate samples were collected every 20 minutes in freely moving animals and analyzed for serotonin levels via high-performance liquid chromatography with electrochemical detection.
resultsAll tested antidepressants significantly elevated extracellular serotonin in the hypothalamus compared to baseline. The magnitude of increase was greatest with clomipramine, followed by sertraline, paroxetine, and fluoxetine. Peak serotonin levels were observed at 120 minutes post-administration for clomipramine and sertraline, whereas paroxetine and fluoxetine peaked at 240 minutes.
conclusionAntidepressant treatment increases hypothalamic serotonin, with clomipramine and sertraline producing the most pronounced effects. Considering that clomipramine and paroxetine combine high serotonergic elevation with notable anticholinergic activity, these drugs may pose a higher risk of voiding difficulties than fluoxetine or sertraline. This study focused on characterizing central serotonergic responses to antidepressant administration as a neurochemical endpoint. The relative risk of voiding difficulty across different antidepressant classes may help guide individualized antidepressant selection. Clinicians should exercise caution when prescribing these agents to elderly patients, individuals with benign prostatic hyperplasia, or those receiving concurrent anticholinergic medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.